Reference
  1. World Health Organization. Cardiovascular diseases (CVDs) Fact Sheet No 317. [Accessed January 2015]. Available from: http://www.who.int/mediacentre/ factsheets/ fs317/en/.
  2. Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci 2017; 13(4): 851-63.
  3. Deepali V, Thomas J, Gupte A. IL-6: An important mediator of obesity based inflammation. International Journal of Advanced and Innovative Research 2013; 2(9): 283-6.
  4. Kaptoge S, Seshasai SR, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 2013; 35(9): 578-89.
  5. Held C, White HD, Stewart RA, et al. Inflammatory biomarkers interleukin‐6 and C‐reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial. J Am Heart Assoc 2017; 6(10): 5077-91.
  6. Abate N, Sallam SH, Rizzo M, et al. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Current Pharmaceutical Design 2014; 20(31): 4961-9.
  7. Fan ZX, Hua Q, Tan J, Gao J, Liu RK, Yang Z. Interleukin-6 but not soluble adhesion molecules has short-term prognostic value on mortality in patients with acute ST-segment elevation myocardial infarction. African J Biotechnol2011; 10(8): 1454-9.
  8. Fan ZX, Hua Q, Li YP, Liu RK, Yang Z. Interleukin-6, but not soluble adhesion molecules, predicts a subsequent mortality from cardiovascular disease in patients with acute ST-segment elevation myocardial infarction. Cell BiochemBiophys 2011; 61(2): 443-8.
  9. Lee JK, Bettencourt R, Brenner D, Le TA, Barrett-Connor E, Loomba R. Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study. PloS One 2012; 7(4): 34218-25.
  10. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013; 339(6116): 161-6.
  11. Wang XH, Liu SQ, Wang YL, Jin Y. Correlation of serum high-sensitivity C-reactive protein and interleukin-6 in patients with acute coronary syndrome. Genet Mol Res 2014; 13(2): 4260-6.
  12. De Gennaro L, Brunetti ND, Montrone D, De Rosa F, Cuculo A, Di Biase M. Subacute inflammatory activation in subjects with acute coronary syndrome and left ventricular dysfunction. Inflammation 2012; 35(1): 363-70.
  13. Ridker PM. Targeting inflammatory pathways for the treatment of cardiovascular disease. Eur Heart J 2014; 35: 540-3.
  14. Lai CL, Ji YR, Liu XH, Xing JP, Zhao JQ. Relationship between coronary atherosclerosis plaque characteristics and high sensitivity C-reactive proteins, interleukin-6. Chinese Med J 2011; 124(16): 2452-6.
  15. Wang XH, Liu SQ, Wang YL, Jin Y. Correlation of serum high-sensitivity C-reactive protein and interleukin-6 in patients with acute coronary syndrome. Genet Mol Res 2014; 13(2): 4260-6.
  16. Velásquez IM, Golabkesh Z, Källberg H, Leander K, de Faire U, Gigante B. Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction. Atherosclerosis 2015; 240(2): 477-81.
  17. Su D, Li Z, Li X, et al. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. Mediators Inflamm 2013; 2013: 726178-85.
  18. Wilkowska A, Pikuła M, Rynkiewicz A, Wdowczyk-Szulc J, Trzonkowski P, Landowski J. Increased plasma pro-inflammatory cytokine concentrations after myocardial infarction and the presence of depression during next 6-months. Psychiatr Pol 2015; 49(3): 455-64.
  19. Ritschel VN, Seljeflot I, Arnesen H, et al. IL-6 signalling in patients with acute ST-elevation myocardial infarction. Results Immunol 2014; 4: 8-13.
  20. Anderson DR, Poterucha JT, Mikuls TR, et al. IL-6 and its receptors in coronary artery disease and acute myocardial infarction. Cytokine 2013; 62(3): 395-400.
  21. Aulin J, Siegbahn A, Hijazi Z, et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J 2015; 170(6): 1151-60.
  22. Mythili S, Malathi N. Diagnostic markers of acute myocardial infarction. Biomed Reports 2015 Nov 1; 3(6): 743-8.
  23. Guo M, Hao M, Tang Y. Relationships among serum IL-6, TNF-α, CRP and coronary artery lesion in patients with acute myocardial infarction. Int J Clin Exp Med 2018 Jan 1; 11: 6987-92.
  24. Athab AM, Saleh MA, Al-dulaimi AA. The role of Interleukin 6, C Reactive Protein, C3and C4 Complement in Immunopathogenesis of Myocardial Infarction. Diyala J Med 2019; 16(2): 39-47.
  25. Todendi PF, Klinger EI, Ferreira MB, et al. Association of IL-6 and CRP gene polymorphisms with obesity and metabolic disorders in children and adolescents. Anais da Academia Brasileira de Ciências 2015 Jun; 87(2): 915-24.
Table 1: Comparison of the demographic and clinical characteristics of patients and healthy control subjects